|
1
|
Tang NP, Wu YM, Wang B, et al: Systematic
review and meta-analysis of the association between P53 codon 72
polymorphism and colorectal cancer. Eur J Surg Oncol. 36:431–438.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valentin MD, da Silva FC, dos Santos EM,
et al: Characterization of germline mutations of MLH1 and MSH2 in
unrelated South American suspected Lynch syndrome individuals. Fam
Cancer. 10:641–647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
da Silva FC, de Oliveira LP, Santos EM, et
al: Frequency of extracolonic tumors in Brazilian families with
Lynch syndrome: analysis of a hereditary colorectal cancer
institutional registry. Fam Cancer. 9:563–570. 2010.PubMed/NCBI
|
|
4
|
Stadler ZK, Vijai J, Thom P, et al:
Genome-wide association studies of cancer predisposition. Hematol
Oncol Clin North Am. 24:973–996. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hollstein M and Hainaut P: Massively
regulated genes: the example of TP53. J Pathol. 220:164–173.
2010.PubMed/NCBI
|
|
7
|
Shi H, Tan SJ, Zhong H, et al: Winter
temperature and UV are tightly linked to genetic changes in the p53
tumor suppressor pathway in Eastern Asia. Am J Hum Genet.
84:534–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mammano E, Belluco C, Bonafé M, et al:
Association of p53 polymorphisms and colorectal cancer: modulation
of risk and progression. Eur J Surg Oncol. 35:415–419. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
The International HapMap Consortium. The
International HapMap Project. Nature. 426:789–796. 2003. View Article : Google Scholar
|
|
10
|
Marin MC, Jost CA, Brooks LA, et al: A
common polymorphism acts as an intragenic modifier of mutant p53
behaviour. Nat Genet. 25:47–54. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Millau JF, Bastien N and Drouin R: P53
transcriptional activities: a general overview and some thoughts.
Mutat Res. 681:118–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu Z, Li X, Yuan R, et al: Three common
TP53 polymorphisms in susceptibility to breast cancer,
evidence from meta-analysis. Breast Cancer Res Treat. 120:705–714.
2010.
|
|
13
|
Siddique MM, Balram C, Fiszer-Maliszewska
L, et al: Evidence for selective expression of the p53 codon 72
polymorphs: implications in cancer development. Cancer Epidemiol
Biomarkers Prev. 14:2245–2252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song HR, Kweon SS, Kim HN, et al: p53
codon 72 polymorphism in patients with gastric and colorectal
cancer in a Korean population. Gastric Cancer. 14:242–248. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cañas M, Morán Y, Camargo ME, et al: TP53
codon 72 polymorphism and gastric cancer risk: a case-control study
in individuals from the central-western region of Venezuela. Invest
Clin. 50:153–161. 2009.(In Spanish).
|
|
16
|
Rogounovitch TI, Saenko VA, Ashizawa K, et
al: TP53 codon 72 polymorphism in radiation-associated human
papillary thyroid cancer. Oncol Rep. 15:949–956. 2006.
|
|
17
|
Granja F, Morari J, Morari EC, et al:
Proline homozygosity in codon 72 of p53 is a factor of
susceptibility for thyroid cancer. Cancer Lett. 210:151–157. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piao JM, Kim HN, Song HR, et al: p53 codon
72 polymorphism and the risk of lung cancer in a Korean population.
Lung Cancer. 73:264–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dai S, Mao C, Jiang L, et al: P53
polymorphism and lung cancer susceptibility: a pooled analysis of
32 case-control studies. Hum Genet. 125:633–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rosenthal AN, Ryan A, Hopster D, et al:
p53 codon 72 polymorphism in vulval cancer and vulval
intraepithelial neoplasia. Br J Cancer. 83:1287–1290. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin HY, Huang CH, Yu TJ, et al: p53 codon
72 polymorphism as a progression index for bladder cancer. Oncol
Rep. 27:1193–1199. 2012.PubMed/NCBI
|
|
22
|
Li DB, Wei X, Jiang LH, et al:
Meta-analysis of epidemiological studies of association of P53
codon 72 polymorphism with bladder cancer. Genet Mol Res.
9:1599–1605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sousa H, Santos AM, Pinto D, et al: Is
there a biological plausability for p53 codon 72 polymorphism
influence on cervical cancer development? Acta Med Port.
24:127–134. 2011.PubMed/NCBI
|
|
24
|
Klug SJ, Ressing M, Koenig J, et al: TP53
codon 72 polymorphism and cervical cancer: a pooled analysis of
individual data from 49 studies. Lancet Oncol. 10:772–784. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li MS, Liu JL, Wu Y, et al: Meta-analysis
demonstrates no association between p53 codon 72 polymorphism and
prostate cancer risk. Genet Mol Res. 10:2924–2933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu Y, Wang J, He Q, et al: Association of
p53 codon 72 polymorphism with prostate cancer: a meta-analysis.
Mol Biol Rep. 38:1603–1607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang W, He X, Chan Y, et al: Lack of
association between p53 codon 72 polymorphism and endometrial
cancer: a meta-analysis. Cancer Epidemiol. 36:153–157. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zubor P, Stanclova A, Kajo K, et al: The
p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in
Caucasian women. Oncology. 76:173–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suresh K, Chandirasekar R, Kumar BL, et
al: No association between the Trp53 codon 72 polymorphism and head
and neck cancer: a case-control study in a South Indian population.
Asian Pac J Cancer Prev. 11:1749–1753. 2010.PubMed/NCBI
|
|
30
|
Mojtahedi Z, Hashemi SB, Khademi B, et al:
p53 codon 72 polymorphism association with head and neck squamous
cell carcinoma. Braz J Otorhinolaryngol. 76:316–320.
2010.PubMed/NCBI
|
|
31
|
Själander A, Birgander R, Athlin L, et al:
P53 germ line haplotypes associated with increased risk for
colorectal cancer. Carcinogenesis. 16:1461–1464. 1995.PubMed/NCBI
|
|
32
|
Gemignani F, Moreno V, Landi S, et al: A
TP53 polymorphism is associated with increased risk of
colorectal cancer and with reduced levels of TP53 mRNA.
Oncogene. 23:1954–1956. 2004.
|
|
33
|
Goodman JE, Mechanic LE, Luke BT, et al:
Exploring SNP-SNP interactions and colon cancer risk using
polymorphism interaction analysis. Int J Cancer. 118:1790–1797.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pérez LO, Abba MC, Dulout FN, et al:
Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the
colon and rectum in La Plata, Argentina. World J Gastroenterol.
12:1426–1429. 2006.PubMed/NCBI
|
|
35
|
Zhu ZZ, Wang AZ, Jia HR, et al:
Association of the TP53 codon 72 polymorphism with
colorectal cancer in a Chinese population. Jpn J Clin Oncol.
37:385–390. 2007.
|
|
36
|
Dakouras A, Nikiteas N, Papadakis E, et
al: p53Arg72 homozygosity and its increased incidence in
left-sided sporadic colorectal adenocarcinomas, in a
Greek-Caucasian population. Anticancer Res. 28:1039–1043. 2008.
|
|
37
|
Koushik A, Tranah GJ, Ma J, et al: p53
Arg72Pro polymorphism and risk of colorectal adenoma and cancer.
Int J Cancer. 119:1863–1868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan XL, Nieters A, Hoffmeister M, et al:
Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs
and the risk of colorectal cancer: evidence for gene-environment
interaction? Pharmacogenet Genomics. 17:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hase K, Shatney C, Johnson D, et al:
Prognostic value of tumor ‘budding’ in patients with colorectal
cancer. Dis Colon Rectum. 36:627–635. 1993.
|
|
40
|
López I, Oliveira PL, Tucci P, et al:
Different mutation profiles associated to P53 accumulation in
colorectal cancer. Gene. 499:81–87. 2012.PubMed/NCBI
|
|
41
|
Goldstein DB: The importance of synthetic
associations will only be resolved empirically. PLoS Biol.
9:e10010082011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Anderson CA, Soranzo N, Zeggini E, et al:
Synthetic associations are unlikely to account for many common
disease genome-wide association signals. PLoS Biol. 9:e10005802011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wray NR, Purcell SM and Visscher PM:
Synthetic associations created by rare variants do not explain most
GWAS results. PLoS Biol. 9:e10005792011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Orozco G, Barrett JC and Zeggini E:
Synthetic associations in the context of genome-wide association
scan signals. Hum Mol Genet. 19:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shields R: Common disease: are causative
alleles common or rare? PLoS Biol. 9:e10010092011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ritchie MD: Using biological knowledge to
uncover the mystery in the search for epistasis in genome-wide
association studies. Ann Hum Genet. 75:172–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dickson SP, Wang K, Krantz I, et al: Rare
variants create synthetic genome-wide associations. PLoS Biol.
8:e10002942010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yan H, Yuan W, Velculescu VE, et al:
Allelic variation in human gene expression. Science. 297:11432002.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bray NJ, Buckland PR, Owen MJ, et al:
Cis-acting variation in the expression of a high proportion
of genes in human brain. Hum Genet. 113:149–153. 2003.
|
|
50
|
Lo HS, Wang Z, Hu Y, et al: Allelic
variation in gene expression is common in the human genome. Genome
Res. 13:1855–1862. 2003.PubMed/NCBI
|
|
51
|
Schadt EE, Monks SA, Drake TA, et al:
Genetics of gene expression surveyed in maize, mouse and man.
Nature. 422:297–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pastinen T, Sladek R, Gurd S, et al: A
survey of genetic and epigenetic variation affecting human gene
expression. Physiol Genomics. 16:184–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cheung VG, Bruzel A, Burdick JT, et al:
Monozygotic twins reveal germline contribution to allelic
expression differences. Am J Hum Genet. 82:1357–1360. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gimelbrant A, Hutchinson JN, Thompson BR,
et al: Widespread monoallelic expression on human autosomes.
Science. 318:1136–1140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Thomas M, Kalita A, Labrecque S, et al:
Two polymorphic variants of wild-type p53 differ biochemically and
biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
|
|
56
|
Dumont P, Leu JI, Della Pietra AC III, et
al: The codon 72 polymorphic variants of p53 have markedly
different apoptotic potential. Nat Genet. 33:357–365. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ozeki C, Sawai Y, Shibata T, et al: Cancer
susceptibility polymorphism of p53 at codon 72 affects
phosphorylation and degradation of p53 protein. J Biol Chem.
286:18251–18260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hancox RJ, Poulton R, Welch D, et al:
Accelerated decline in lung function in cigarette smokers is
associated with TP53/MDM2 polymorphisms. Hum Genet.
126:559–565. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pandith AA, Shah ZA, Khan NP, et al: Role
of TP53 Arg72Pro polymorphism in urinary bladder cancer
predisposition and predictive impact of proline related genotype in
advanced tumors in an ethnic Kashmiri population. Cancer Genet
Cytogenet. 203:263–268. 2010.
|
|
60
|
Tobacco Free Initiative (TFI). WHO report
on the global tobacco epidemic, 2011: warning about the dangers of
tobacco. World Health Organization; 2011, Available at http://www.who.int/tobacco/global_report/2011/en/.
|
|
61
|
Marqueta A, Nerín I, Jiménez-Muro A, et
al: Predictors of outcome of a smoking cessation treatment by
gender. Gac Sanit. 27:23–31. 2012.(In Spanish).
|
|
62
|
Hiscock R, Bauld L, Amos A, et al:
Socioeconomic status and smoking: a review. Ann NY Acad Sci.
1248:107–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Norppa H: Cytogenetic biomarkers and
genetic polymorphisms. Toxicol Lett. 149:309–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Vodicka P, Kumar R, Stetina R, et al:
Genetic polymorphisms in DNA repair genes and possible links with
DNA repair rates, chromosomal aberrations and single-strand breaks
in DNA. Carcinogenesis. 25:757–763. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hanova M, Vodickova L, Vaclavikova R, et
al: DNA damage, DNA repair rates and mRNA expression levels of cell
cycle genes (TP53, p21CDKN1A,
BCL2 and BAX) with respect to occupational exposure
to styrene. Carcinogenesis. 32:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jass JR, Love SB and Northover JM: A new
prognostic classification of rectal cancer. Lancet. 1:1303–1306.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zlobec I, Baker K, Minoo P, et al: Tumor
border configuration added to TNM staging better stratifies stage
II colorectal cancer patients into prognostic subgroups. Cancer.
115:4021–4029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zlobec I, Terracciano LM and Lugli A:
Local recurrence in mismatch repair-proficient colon cancer
predicted by an infiltrative tumor border and lack of
CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res.
14:3792–3797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Grochola LF, Zeron-Medina J, Mériaux S, et
al: Single-nucleotide polymorphisms in the p53 signaling pathway.
Cold Spring Harb Perspect Biol. 2:a0010322010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wilkinson NW: Adjuvant chemotherapy for
colorectal cancer-new perspectives for effective treatment. US
Gastroenterol Hepatol Rev. 1:91–93. 2007.
|
|
71
|
Casillas S, Pelley RJ and Milsom JW:
Adjuvant therapy for colorectal cancer: present and future
perspectives. Dis Colon Rectum. 40:977–992. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fuchs CS and Mayer RJ: Adjuvant
chemotherapy for colon and rectal cancer. Semin Radiat Oncol.
3:29–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Naccarati A, Polakova V, Pardini B, et al:
Mutations and polymorphisms in TP53 gene: an overview on the
role in colorectal cancer. Mutagenesis. 27:211–218. 2012.
|
|
75
|
Sullivan A, Syed N, Gasco M, et al:
Polymorphism in wild-type p53 modulates response to chemotherapy
in vitro and in vivo. Oncogene. 23:3328–3337. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pim D and Banks L: p53 polymorphic
variants at codon 72 exert different effects on cell cycle
progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bergamaschi D, Samuels Y, Sullivan A, et
al: iASPP preferentially binds p53 proline-rich region and
modulates apoptotic function of codon 72-polymorphic p53. Nat
Genet. 38:1133–1141. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nelson HH, Wilkojmen M, Marsit CJ, et al:
TP53 mutation, allelism and survival in non-small cell lung
cancer. Carcinogenesis. 26:1770–1773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tommiska J, Eerola H, Heinonen M, et al:
Breast cancer patients with p53 Pro72 homozygous genotype have a
poorer survival. Clin Cancer Res. 11:5098–5103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xu Y, Yao L, Ouyang T, et al: p53 codon 72
polymorphism predicts the pathologic response to neoadjuvant
chemotherapy in patients with breast cancer. Clin Cancer Res.
11:7328–7333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Petitjean A, Mathe E, Kato S, et al:
Impact of mutant p53 functional properties on TP53 mutation
patterns and tumor phenotype: lessons from recent developments in
the IARC TP53 database. Hum Mutat. 28:622–629. 2007.PubMed/NCBI
|
|
82
|
Bougeard G, Baert-Desurmont S, Tournier I,
et al: Impact of the MDM2 SNP309 and p53 Arg72Pro
polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med
Genet. 43:531–533. 2006.
|
